期刊
CLINICA CHIMICA ACTA
卷 476, 期 -, 页码 178-184出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.cca.2017.11.022
关键词
Glioma; Tim-3; NK; Monocyte
资金
- National Natural Science Fund for Outstanding Youth Fund [81425012]
- National Key Research and Development Program [2016YFE0127000]
- National Science Foundation of China [81425012, 81372211, 81672425]
- Key Research & Development Plan of Shandong Province [2016ZDJS07A17, 2017GSF18185, ZR2014HM067]
Malignant glioma, the most common and devastating primary brain tumor, has serious effects on human health with high risk of recurrence and short survival periods. Recently, the exploitation of immunological mechanisms shed-new lights for developing novel therapeutic strategies for glioma pathogenesis. Tim-3, a member of T cell immunoglobulin and mucin domain family, has been involved in multiple diseases, including tumor, by regulating the viability and function of immunocytes. In the present study, we detected Tim-3 expression on peripheral innate immunocytes from glioma patients and analyzed their correlation with clinical indices. We found that the number of CD3(-) CD56(+) NK cells decreased in glioma patients. Compared with healthy controls, glioma patients had higher Tim-3 expression on peripheral CD3(-) CD56(+) NK cells and CD14(+) monocytes. Tim-3(+) NK cells had decreased capability of IFN-r secretion, while Tim-3(+) monocytes showed a M2-like phenotype. Importantly, Tim-3 level on both NK cells and monocytes positively correlated with the ratio of Ki-67(+) tumor cells. Moreover, patients with high percentage of Tim-3(+) monocytes showed high risk of recurrence or death. Our present work gives new insights into the innate immune mechanisms in glioma and might provide new evidences for the clinical practice of Tim-3-based immunotherapy in glioma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据